A practical reference on Heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-04 and is reviewed periodically as new material appears.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
== Receptors involved in platelet adhesion to collagen == Membrane glycoproteins GPIa/IIa, GPVI and probably GPIV as well, function as collagen receptors, engaged in platelet adhesion to collagen. The leading role in the elimination of high-stress injury is taken by the glycoprotein Ib-IX-V complex.
Bethlem myopathy may be diagnosed based on clinical examinations and laboratory tests may be recommended. Genetic testing for known pathological variants is preferred. In the case of a VUS, testing of dermal fibroblast culture is used for an accurate diagnosis. Bethlem myopathy 1 is a rare disease, affecting about 1 in 200,000 people. Bethlem myopathy 2 is an ultra-rare disease, affecting less than 1 in 1,000,000 people. The condition was described by J. Bethlem and G. K. van Wijngaarden in 1976.
=== Urogynaecological === Weakened connective tissues can lead to pelvic organ prolapse in female patients with EDS. Patients may also experience voiding difficulties, frequent urinary tract infections, and incontinence due to structural abnormalities. Pelvic girdle pain is also frequently reported. Menorrhagia, dysmenorrhea, and dyspareunia are common symptoms associated with EDS and are often mistaken for endometriosis. Excessive menstrual bleeding can sometimes be attributed to inappropriate platelet aggregation, but faulty collagen leads to weakened capillary walls, which increase the likelihood of hemorrhage. In cases of pregnancy, patients with EDS are likelier to experience complications during parturition. Post-partum hemorrhage and maternal injury, such as sporadic pelvic displacement, hip dislocation, torn and stretched ligaments, and skin tearing, can all be linked to the altered structure of connective tissues.
Sources: en.wikipedia.org
One possibility for making the theorized long-lived nuclei of copernicium (291Cn and 293Cn) and flerovium near the middle of the island, is using even heavier targets such as 250Cm, 249Bk, 251Cf, and 254Es, that when fused with 48Ca would yield isotopes such as 291Mc and 291Fl (as decay products of 299Uue, 295Ts, and 295Lv), which may have just enough neutrons to alpha decay to nuclides close enough to the centre of the island to possibly undergo electron capture and move inward to the centre. However, reaction cross sections would be small and little is yet known about the decay properties of superheavies near the beta-stability line. This may be the current best hope to synthesize nuclei in the island of stability, but it is speculative and may or may not work in practice. Another possibility is to use controlled nuclear explosions to get the high neutron flux needed to make macroscopic amounts of such isotopes. This would mimic the r-process where the actinides were first produced in nature and the gap of instability after polonium bypassed, as it would bypass the gaps of instability at 258–260Fm and at mass number 275 (atomic numbers 104 to 108). Some such isotopes (especially 291Cn and 293Cn) may even have been synthesized in nature, but would decay far too quickly (with half-lives of only thousands of years) and be produced in far too small quantities (~10−12 the abundance of lead) to be detectable today outside cosmic rays.
== Toxicity == Phenformin sales began to decline in the U.S. from 1973 due to negative trial studies and reports of lactic acidosis. By October 1976, the U.S. Food and Drug Administration (FDA) Endocrinology and Metabolism Advisory Committee recommended phenformin be removed from the market. The FDA began formal proceedings in May 1977, leading to Phenformin's eventual withdrawal on November 15, 1978. In 1977, 385,000 patients with early-stage diabetes were taking phenformin in the U.S.. Ralph Nader's Health Research Group put the U.S. government under pressure to ban the drug. Ciba-Geigy Corp resisted, claiming there was no satisfactory alternative for many patients. But in July the FDA declared the drug an "imminent hazard to the public health" and gave doctors 90 days to switch to an alternative treatment (such as insulin, dietary restrictions or other drugs). As of 2008, phenformin was still legally available in Italy, Brazil, Uruguay, China, Poland, Greece and Portugal and cases of phenformin-induced lactic acidosis continued to be reported worldwide. In Hong Kong, where phenformin is banned, cases of phenformin-induced lactic acidosis occurred after taking Chinese proprietary medicines, claiming to be herbal, which were adulterated with phenformin. In the U.S., in 2001 the FDA recalled Chinese "herbal products" containing phenformin.
==== Missiles and drones ==== Since established in 2003, Hezbollah's Unit 3800 has provided the Houthis training and strategic assistance. Iran's Quds Force has smuggled weapons to the Houthis since 2009, mainly using dhows and small fishing boats. It began smuggling missile components as well by 2015. Between 2004 and 2010, the Houthis frequently looted Yemeni government weapons caches, which included Scud and OTR-21 Tochka missiles obtained during the 1994 Yemeni civil war, due to weak government control over its arsenal. In 2017, the UN reported that about 70% of the Yemeni military's weapons were likely lost. In March 2015, the Saudi-led coalition claimed that it had destroyed most of the Houthis' missile capabilities during an air campaign, however Houthi missile attacks persisted. The Houthis, with technological help from Iran, began work on new missile variants by mid-2016, and by September they introduced the Burkan-1, a variant of the Scud with extended range. The following month, they introduced the Burkan-2H, which had a separating warhead. These weapons enabled the Houthis to strike targets deep in Saudi Arabia, including the capital Riyadh. After examining debris from the Burkan-2H, the UN concluded in December 2017 that the missile was supplied by Iran. Late in 2015, Houthis announced the local production of short-range ballistic missile Qaher-1 on Al-Masirah TV. On 19 May 2017 Saudi Arabia intercepted a Houthi-fired ballistic missile targeting a deserted area south of the Saudi capital and most populous city Riyadh.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.